The Review Of
DIABETIC
STUDIES OPEN ACCESS

The Interplay Of Endocrine Disorders And Chronic Hematological Diseases In Cancer And Viral Infections

Dr.Ashjan A Alrogi[1] , Dr-Ebtesam S. Allehaibi[2] , Dr-Ahmed Abdullah Saad Alghamdi[3] , Dr-Latifah Eid aljohani[4] , Dr-Manhal Nabeel Redwan[5] , Dr- Ameerah Abdulkareem Alsaedi[6] , Dr. Salwa abdulrahman Hawsawi[7] , Dr Ghaydaa Abdulrhman Aborreesh[8] , Dr- Lamees Ismaeel hussain filimban[9] , Dr -Hamzah Khalid Qul[10]

[1]Internal medicine/ Adult Endocrinology Hera general hospital
[2]Consultant endocrinologist and internal medicin king abdulaziz hospital
[3]Consultant Internist/Endocrinologist King Abdulaziz Hospital
[4]Adult hematology General King abdulaziz hospital
[5]Internist and adult endocrinologist Diabetic and Endocrine Center, AlNoor hospital
[6]Internist and adult endocrinologist Diabetic and Endocrine Center, AlNoor hospital,
[7]Internal medicine/ Adult Endocrinology Hera general hospital
[8]General internist King Faisal hospital Makkah
[9]Endocrine and diabetes consultant King Abdullah medical complex Jeddah
[10]Internist and adilt endocrinologist king Abdulaziz hospital makkah

Abstract
Hormones are intimately involved in the regulation of hematopoiesis, and many hematological functions are modulated by hormones. Circulating hormones and hematological functions must be viewed as part of an integrated process of physiological regulation. It remains uncertain whether these early observations of hematological irregularities should be considered merely pre-existing chronic conditions or subsequent complications of endocrine disorders.

The immunological arsenal is under the influence of endocrine disorders, and in cases of cancer and viral infection, either the immunosurveillance outmatches the disease or the host succumbs due to immunological failure (Fernanda Pascutti et al., 2016) (Tsilingiris et al., 2022). Endocrine-hematological concomitants of oncological and virally infected patients draw considerable attention in the context of their clinical management.

1. Introduction

The associations between endocrine disorders and chronic hematological diseases are of significant medical interest. Understanding their immunological impact is essential when addressing major problems such as cancer or viral infections. Endocrine disorders may lead to alterations in the immune response and hematological alterations. Conversely, chronic hematological diseases can impair endocrine function, indicating a bidirectional and highly relevant interplay.

Endocrine disorders encompass deficiencies or excesses of hormones produced by the endocrine system, often involving glandular dysfunction. These alterations can induce various hematological changes, including anemia, erythrocytosis, myeloma, or thrombocytopenia (Fernanda Pascutti et al., 2016). In patients with chronic hematological diseases, endocrine disorders are multifactorial and arise secondary to treatments such as chemotherapy and radiotherapy. The implantation of hematopoietic stem cells further complicates endocrine function. Beyond the hormonal alterations

stemming from cancer and its therapies, the neoplastic process itself predisposes individuals to a multitude of endocrine abnormalities—some clinically evident, others subclinical—thereby necessitating long-term monitoring.

Chronic hematological diseases constitute a group of disorders characterized by the neoplastic proliferation of hematopoietic cells; they are classified according to the affected cell lines, including lymphomas (lymphocyte line), multiple myeloma (plasma cells), leukemias (myeloid or lymphoid lines), and myelodysplastic syndromes. Hematological diseases can induce primary endocrine disorders, with an increased risk of malignancy being a prominent complication. Both conditions thus frequently coexist.

Immunology mediates the interplay between endocrine disorders and chronic hematological diseases. The immune system is the intermediary factor governing the relationship between these two groups of pathologies.

2. Overview of Endocrine Disorders

Endocrine disorders are endocrine system disorders in which out-of-control cell growth results in the formation of masses called tumors, which can be either malignant or benign. Endocrine tumors affect the endocrine glands (thyroid gland, adrenal gland, and pituitary gland, among others) and often cause increased or decreased secretion of one or more hormones. Endocrine tumors are generally rare, but are among the more common malignancies arising in children and adolescents. Similarly, inherited endocrine tumors are rare, but identification of an inherited disorder can have significant implications for patient and family.

Endocrine disorders are a diverse group of diseases involving abnormal hormone secretion by the endocrine system that produces pathological effects on other organs or systems. The pituitary, thyroid, parathyroid, adrenal, and pancreatic glands produce many of the hormones that influence physiological function. Conversely, the immune system has been shown to influence the function and growth of these same endocrine glands. Endocrine disorders include diseases of hyposecretion and hyporesponsiveness, and diseases of hypersecretion and hyperresponsiveness. Several endocrine disorders induce abnormalities in red blood cells, white blood cells, and platelets that directly influence hematological indices (Fernanda Pascutti et al., 2016). These endocrine abnormalities can define the progression or aggressiveness of a chronic hematological disease and influence the response to therapeutic agents.



Image 1: Conceptual Diagram of the Endocrine-Hematological-Immune Axis

3. Chronic Hematological Diseases: A Comprehensive Review

Chronic hematological diseases impose a profound burden with morbidity and mortality globally. The World Health Organization identifies anaemia, haemoglobinopathies, G6PD deficiency, haemophilia, leucopaenia, thrombocytopaenia, and malignancies as principal chronic haematological conditions warranting prioritization. Anaemia constitutes the most widespread form, affecting 25% of the global populace and causing substantial disability. Concurrently, cancer and viral infections markedly impact endocrine function, which, through the immune system, in turn modulates haematopoiesis and haematological pathology (Kedia et al., 2014). Chronic haematological disease thus represents a critical dimension within this domain.

Erythrocyte abnormalities unravel into anaemia, polycythaemia, or erythrocytosis while leucocyte dysregulation manifests as either leucopaenia or leucocytosis, with further segmentation into lymphocytopenia, neutropenia, or eosinopaenia. These entities originate from diverse etiologies including nutritional insufficiencies, genetic impairments, external irritants, intrinsic malignancies, and haemorrhagic episodes. Complementarily, thrombocytopenia and bone marrow failure syndromes delineate additional chronic haematological disorders subject to broad classification (Fernanda Pascutti et al., 2016).



Figure 1: Comparison of the global prevalence of related health conditions

4. The Role of the Immune System in Endocrine and Hematological Interactions

The endogenous machinery that the organism has developed to fight infection can be taken over by the virus itself. For instance, retroviruses can directly target microRNAs, crucial post-transcriptional regulators of gene expression that allow the host to control and clear viral infections, by inhibiting these cellular pathways (Fernanda Pascutti et al., 2016).

According to their pathomechanism and clinical features, endocrine diseases can be divided into hypothalamic–pituitary diseases, thyroid–parathyroid diseases, metabolic diseases, and bone metabolism diseases. Indeed, a number of hormones directly or indirectly regulate the

hematopoietic system and/or the immune system, and endocrine disorders manifest themselves with huge hematological alterations with important immune consequences.

5. Impact of Endocrine Disorders on Hematological Health

Hormones regulate numerous physiological processes and are vital for homeostatic control, development, and reproduction. Hormonal changes profoundly affect immunity and hematopoiesis; endocrine disorders frequently induce hematological abnormalities in experimental settings and clinical practice. Many chronic hematological diseases (CHDs) are associated with endocrine disorders. Because the endocrine and hematological systems cooperate to support vertebrate development, alterations in these systems often coincide. The immune system acts as the central link between endocrine disorders and CHDs, given the significant immunological components of both. Interrupting this network can impair immune responses, causing immune deficiencies that endanger patient prognosis. Patients with either endocrine or hematological disorders are at increased risk of cancer and viral invasion, as these conditions interfere with immunological functions. Several reported cases highlight the immunological strains imposed by concurrent endocrine and hematological disorders. History and physical data are critical, enabling diagnosis of CHDs through laboratory and radiological evaluation of patients with endocrine disorders or behaviour indicative of endocrine dysfunction. Autoimmune, neoplastic, functional haematological disorders, and paraneoplastic syndromes contribute to endocrine disease and malignancy (Ostadrahimi et al., 2022). Malignant haematological diseases also commonly cause endocrine complications (Fernanda Pascutti et al., 2016).

Malignant haematological diseases are a heterogeneous group of disorders affecting blood cell production and immune function. The immune system is crucial to hematopoietic homeostasis, and disruption of signaling induces hematological disorders that affect immune cell production and function. Endocrine disorders influence immune cell production through the release of steroid hormones, glucocorticoids, and sex hormones that modulate haematopoietic stem cell maintenance and differentiation. Endocrine disorders induce a heterogeneous group of haematological disturbances, including red blood cell abnormalities, leukopenia or leukocytosis, neutropenia, lymphopenia, eosinophilia, basophilia, bi-cytopenia or pancytopenia, myelodysplastic syndromes (pre-leukaemic disorders), and myeloproliferative syndromes (haemopoietic individual or bi-lineage disorders). Haematological manifestations arise through malnutrition, auto-immunity, haemorrhage, infections, or the toxic effect of drugs.

Endocrine Disorder Category	Specific Condition / Hormonal Imbalance	Associated Hematological Manifestations
Thyroid Diseases	Hypothyroidism	Anemia (normocytic, macrocytic, or microcytic)
	Hyperthyroidism	Mild erythrocytosis, alterations in coagulation factors
Adrenal Gland Disorders	Hypercortisolism (Cushing's Syndrome)	Erythrocytosis, neutrophilic leukocytosis, eosinopenia, lymphopenia, increased risk of thrombosis
	Adrenal Insufficiency (Addison's Disease)	Normocytic anemia, neutropenia, lymphocytosis, eosinophilia

Pituitary Gland Disorders	Hypopituitarism	Anemia, leukopenia
	Acromegaly (Excess Growth Hormone)	Mild erythrocytosis, increased red cell mass
Gonadal Disorders	Hypogonadism (in males)	Mild normocytic anemia
Parathyroid & Metabolic	Hyperparathyroidism	Anemia, potential bone marrow fibrosis
	Diabetes Mellitus	Altered red cell survival, platelet hyper-reactivity, impaired leukocyte function

Table 1: Hematological Manifestations of Common Endocrine Disorders

6. Chronic Hematological Diseases and Their Endocrine Consequences

The interplay between endocrine and chronic hematological diseases has exerted a strong complex influence, affecting the setting of cancer and viral infection. Viral infections remain a major cause of morbidity. In this scenario, endocrine disorders present a strong immunological impact that dramatically alters the haemopoiesis. Furthermore, cancer is known to be associated with an increased incidence of hematologic abnormalities characterized by anaemia and coagulation-disorders resulting in abnormal bleeding or thromboembolism. Moreover, hematologic disorders can be concomitant with acute viral infections in the setting of endocrine deficiencies (Michele Carella et al., 2015). Chronic hematological diseases affect approximately 50 per 100 000 in Europe affecting all subtypes of age, with higher incidence in young adults, adolescents and children. A great number of these diseases are chronic and immunocompromised treatment is persistently required. The endocrine system seems to be affected either because of the disease itself or as a consequence of the treatment. Both scenarios present crucial consequences often overlooked by both hematologists and endocrinologists (Fernanda Pascutti et al., 2016).

7. Cancer: A Dual Challenge of Endocrine and Hematological Disorders

The coexistence of chronic endocrine disorders and chronic hematological diseases affects the immune system and may have distal effects on cancer and viral infection. While these effects have been studied separately, the combined impact is less well understood.

The structure and function of the endocrine system provide useful insight into the role and consequences of endocrine diseases. The glands of the endocrine system produce hormones that control many bodily functions. Hormones are chemical compounds that elicit a response in a particular tissue or organ—the target—through interaction with a receptor.

Common chronic diseases of the blood are associated with tissue oxygenation, the immune system, and clotting. Understanding the aetiology of these diseases provides insight into the issues generated by chronic endocrine abnormalities.

Interactions between the endocrine and hematological systems have gained interest in recent years. Endocrine disorders have a substantial global healthcare impact and many have associated hematological abnormalities. These abnormalities may be secondary to the endocrine condition, or the treatment thereof, and at times are the cause of the initial endocrine presentation.

The immune system is a sequential cascade that relies on prompt identification of the target to initiate and regulate an appropriate response. The immune system is crucial to the survival of the individual and is often impaired by conditions such as chronic endocrine disorders, chronic hematological diseases, cancer, and viral infections (Zorina & Styche, 2015) (Tsilingiris et al., 2022).

An important result of endocrine disorders is the effect on hematology, most notably coagulation and cell counts. The endocrine system and hematology are closely interrelated; abnormalities in one system have reflections in the other that may vary from mild to life-threatening.

Chronic hematological diseases also have endocrine consequences, often arising from bone marrow invasion or myelosuppression. The endocrine and hematological systems are so closely aligned that a pathological event will rapidly affect both systems.

Cancer presents a dual challenge in the expression of both endocrine disorders and chronic hematological diseases. Multiple hematological abnormalities increase the normal cumulative effect of endocrine disorders on the immune system. The resultant immune depression leaves patients predisposed to recurrent and protracted infections. The presence of endocrine disorders may arise as a pre-existing condition, the result of the pathological process or treatment complications.

8. Viral Infections and Their Influence on Endocrine Function

Viral infections can cause alterations in endocrine function through the direct effects of the virus or through immune or inflammatory mediators that act on endocrine tissues (Pandoua Nekoua et al., 2023). Many viruses target haematopoietic stem and progenitor cells (HSPCs), including cytomegalovirus (CMV), hepatitis C virus, and Herpes viruses such as human herpes virus-7, which is capable of infecting HSPCs and impairing their survival and proliferation (Fernanda Pascutti et al., 2016). Parvovirus B19 has a selective tropism for erythroid lineage cells and is implicated in transient or persistent erythroid aplasia during infection. Retroviruses such as the human immunodeficiency viruses (HIV) and human T-cell leukaemia virus (HTLV) target microRNAs to manipulate cellular pathways, resulting in haematopoietic malignancies.

9. Immunological Implications of Endocrine and Hematological Interactions

Endocrine and chronic hematological diseases frequently coexist (Veronica Suarez et al., 2015) , and because of the immunological impact of such an association in cancer and viral infections, concurrent endocrine disorders and chronic hematological conditions represent medical challenges that require integrated and interdisciplinary patient care. The immune system plays a key role in modulating the interplay between endocrine and hematological disorders (Fernanda Pascutti et al., 2016). Endocrine and immune systems are connected through multiple regulatory pathways; in particular, the anti-inflammatory and immune-suppressive actions of glucocorticoids. Several cytokines regulate the endocrine system, and numerous hormones possess immunomodulatory properties. The immune response to bacterial, viral, and parasitic infections is associated with altered hormonal responses, and therefore, immune-endocrine interactions appear to play a role in the host's defence against pathogens. Proinflammatory cytokines induce the hypothalamic-pituitary-adrenal (HPA) axis to release glucocorticoids (GCs), which suppress the immune system to prevent unremitted and deleterious inflammatory and immune reactions. Nevertheless, accumulating evidence shows that glucocorticoids can be simultaneously pro- and anti-inflammatory and are required for the development of some immune processes. Activation of the HPA axis is followed by the release of adrenal hormones such as dehydroepiandrosterone (DHEA), which exert immunostimulatory and antiglucocorticoid effects. GCs inhibit the production of both Th1 and Th2 cytokines and consequently shift the T cell balance towards a Th2-mediated response. Conversely, DHEA promotes Th1 responses by inducing the production of IL-2 and IFN-γ and by

suppressing IL-4 and IL-5. In addition to acting on the immune system through cellsurface receptors, DHEA regulates the expression of several proteins involved in antioxidant and antiglucocorticoid actions and in cell survival. DHEA enhances protective immune responses against pathogens. During infection, pathogens modulate endocrine functions either directly or through soluble mediators secreted by host cells.

Mediator / Hormone	Primary Source	Effect on Immune System
Glucocorticoids (GCs)	Adrenal glands (stimulated by HPA axis)	Primarily immunosuppressive; inhibit Th1 and Th2 cytokine production, shifting balance to Th2 response. Can also be pro-inflammatory.
Dehydroepiandrosterone (DHEA)	Adrenal glands	Immunostimulatory and antiglucocorticoid effects. Promotes Th1 responses by inducing IL-2 and IFN-γ production.
Proinflammatory Cytokines (e.g., IL-1, IL-6, TNF-α)	Immune cells during infection/inflammation	Induce the Hypothalamic-Pituitary-Adrenal (HPA) axis to release glucocorticoids.
Sex Hormones (e.g., Estrogen, Androgens)	Gonads	Modulate hematopoietic stem cell maintenance and differentiation. Estrogen is linked to female-predominant autoimmune endocrinopathies.
Thyroid Hormones	Thyroid gland	Impact hematological parameters through complex immune-mediated pathways.

Table 2: Key Immunological Mediators in the Endocrine-Hematological Axis



Image 2: Pathways of Hormonal Influence on Immune Cells

10. Case Studies: Endocrine Disorders in Cancer Patients

Endocrine interactions with hematological function in chronic disease states have received limited consideration to date, despite some evidence showing impairment of hematological function in cases of the most common endocrine disturbances. Endocrine disorders represent a group of pathological conditions that affect hormone secretion and metabolism, impacting hormonal recovery, physiological homeostasis, immune integrity, and lymphoproliferation upfront. Chronic haematological diseases correspond to inherited or acquired haematological disorders, with considerable immune and clinical impact in malignancy and viral infection.

Endocrine diseases have a 10–15% prevalence and a strong immunological impact, considering the multifactorial pathways that affect immunological response, inflammation, lymphocyte population, cell repair, and the proliferative environment, including oncogenesis and mutagenesis (Güemes et al., 2022). Recognising the role of endocrine disruptions in modulating immune pathways is key to understanding subsequent effects on haematological health.

Chronic haematological diseases are common disorders that impair immune, cellular, and organ function, either as a latent defect or secondary to the acute disease itself. Some haematological diseases present a high risk of infection and clinical complications, and present an 8-time higher mortality rate following SARS-COV-2 infection. They are classified as inherited and acquired, and although prevalent in several pathologies, they also represent an independent mechanism of lymphoproliferation (Carvalho et al., 2022). Haematological disorders can impact endocrine function in surviving cancer patients, with common sequelae including inadequate pubertal development, hypothyroidism, and bone metabolism disturbances. An intricate cross-talk is established, with a double impact in malignant oncological or viral infection cases.

When haematological disorders and endocrine disorders affect the same population, as in viral infection and solid cancers, an exponential escalation of the immune, clinical, and prognostic impact occurs. Linking both groups of disorders with the severe and altered immune and haematological responses in cancer and viral infection, a comprehensive comprehension of the underlying interplay and its repercussions in inflammatory, opportunistic, proliferative, and mutagenetic characteristics is required. As such, the impact of endocrine disorder and haematological disorder within a cancer or viral infection context needs to be addressed from the immunological perspective, informing an integrated approach for interdisciplinary and personalised patient care.

11. Case Studies: Hematological Disorders in Viral Infections

Viral infections have an enduring impact on haematopoiesis, with both direct viral infection and virus-specific immune responses disrupting bone marrow output. Viruses such as CMV, HCV, and herpesviruses may directly infect haematopoietic stem and progenitor cells (HSPCs), causing myelosuppression and reducing HSPC survival and proliferation; parvovirus B19 targets erythroid progenitors, leading to blocked erythropoiesis. Retroviruses like HIV and HTLV manipulate cellular pathways via microRNAs, contributing to haematopoietic malignancies, while SIV-associated protein Nef can induce haematopoietic defects. Indirectly, inflammatory mediators and alterations in the bone marrow microenvironment further affect haematopoietic function (Fernanda Pascutti et al., 2016). Chronic HCV infection, influencing approximately 3% of the global population, frequently entails haematological manifestations including cytopenias, coagulopathy, and lymphoproliferative disorders. Immune and non-immune thrombocytopenia are prevalent, particularly in advanced liver disease, yet treatments such as steroids, immunoglobulins, splenectomy, and immunosuppressants offer limited benefit and may exacerbate viral load or provoke thrombotic events. Eltrombopag has emerged as a promising agent for platelet restoration

prior to antiviral therapy, although its preoperative application has yielded unexpected complications. Antiviral regimens commonly induce anemia and neutropenia, compounding haematological challenges. The virus predisposes to lymphoproliferative diseases—predominantly non-Hodgkin's lymphomas—through chronic antigenic stimulation, cytokine dysregulation, and genetic mutations affecting carcinogenesis pathways; here, antiviral therapy demonstrates noteworthy efficacy. Management of diffuse large B-cell lymphoma in HCV-infected individuals mandates vigilant monitoring of hepatic function and viral load to prevent reactivation. Ongoing research pursues optimized therapeutic strategies to address these intersecting haematological and virological landscapes (Kedia et al., 2014). Immunological imbalances may partially account for these associations and the progression of concurrently evolving diseases. To avoid independent laboratory approaches, integrated patient treatment encompassing analysed concomitant conditions is essential.

Virus	Primary Target in Hematopoietic System	Direct Hematological Consequences	Mechanism of Action
Cytomegalovirus (CMV)	Hematopoietic Stem and Progenitor Cells (HSPCs)	Myelosuppression	Direct infection and impairment of HSPC survival and proliferation
Hepatitis C Virus (HCV)	HSPCs, B-lymphocytes	Cytopenias, coagulopathy, lymphoproliferative disorders (e.g., Non-Hodgkin's lymphoma)	Chronic antigenic stimulation, cytokine dysregulation, direct infection of HSPCs
Parvovirus B19	Erythroid lineage cells / Erythroid progenitors	Transient or persistent erythroid aplasia (pure red cell aplasia)	Selective tropism for and destruction of erythroid progenitor cells, leading to blocked erythropoiesis
Human Immunodeficiency Viruses (HIV)	MicroRNAs in hematopoietic cells	Hematopoietic malignancies, hematopoietic defects	Manipulation of cellular pathways via microRNAs
Human Herpesvirus 7 (HHV-7)	Hematopoietic Stem and Progenitor Cells (HSPCs)	Impaired HSPC survival and proliferation	Direct infection of HSPCs

Table 3: Impact of Viral Infections on Hematopoiesis



Image 2: Visual Representation of Myelosuppression Caused by Viral Infection

12. Therapeutic Approaches to Manage Endocrine and Hematological Issues

The understanding and management of endocrine and chronic hematological disorders is conducted through bidirectional flowcharts outlining their evolution alongside different pathologies and various therapeutic options. These approaches underscore the importance of examining conditions such as hypercortisolism, hypovitaminosis D, thyroid, and gonadal disorders to appreciate their interplay with chronic hematological diseases—information crucial for formulating effective integrated treatments. Therapeutic strategies aim to prevent, facilitate, correct, and integrate oncological treatments without undesirable alterations; for example, by excluding drugs that exacerbate hematochemical and hematological changes. Tailored therapeutic supplements are employed to reverse hematological disorders, control iron metabolism, and reduce thromboembolic risks associated with hematological diseases. These interventions are fundamental for preserving immune homeostasis in patients with cancer and viral diseases (Andreazzoli & Bonucci, 2023).

Diseases characterized by a disrupted immune response, such as cancer and viral infections, frequently exhibit a combined endocrine and hematological profile that involves altered hematological determinations and endocrine disorders. Specific clinical cases highlight the therapeutic challenges encountered in managing these multifaceted conditions (Kedia et al., 2014). The shared objective of sustaining immune homeostasis constitutes the framework for approaches to such complex scenarios, emphasizing the need for integrated patient care (Michele Carella et al., 2015).

13. The Importance of Early Diagnosis and Management

An early diagnosis of the metabolic or haematological disorders related to cancer or viral infections is of paramount importance in the management of the patients.

Endocrine complications during haematological malignancies are quite common and may be the consequence of either systemic effects of the tumour or specific antineoplastic treatments. It was demonstrated that individual aspects of the metabolic syndrome or specific endocrine disorders have a relevant impact on the outcome of neoplastic and non neoplastic haematological conditions

(Michele Carella et al., 2015). Thus, it becomes imperative to understand as many details as possible about their pathologic mechanisms in order to optimise the treatment and the follow up.

In one hand the haematological abnormalities may be the consequence of an endocrine complication and in the other hand a similar interplay may take place in the opposite direction (all accentuated due to the interference of the tumour growth or neoangiogenesis). An endocrine tumour may also have a direct impact on one or many systems involved in the haematological abnormalities.

Nevertheless, the urease-producing bacteria or the virus infections may have a similar impact since there is ample literature to envisage that haematological abnormalities may induce endocrine disorders, frequently leading to the exacerbation of the symptoms and, ultimately, of the outcome.

14. Future Directions in Research

The complex interaction between the endocrine and haemopoietic systems must be taken into consideration during the management of both neoplastic and infectious diseases. The haemopoietic elements occupy specific micro-environmental niches within the bone marrow, which are primarily controlled by cellular and humoral signals originating from the endocrine and immune systems. Diseases of one of these systems inevitably have a direct and important impact on the relative functions of the others. Endocrine pathology, in addition to its direct influence on immune competence, also plays a central haemopoietic role and thus on the immunological disarrangement encountered in cancer and during certain viral infections (Andreazzoli & Bonucci, 2023) (Fernanda Pascutti et al., 2016).

15. Patient Perspectives: Quality of Life Considerations

Quality of life is an important aspect of patient care in chronic haematological cancers. People with these diseases often live for many years without apparent progression of their condition. Moreover, while treatment of advanced disease can result in prolonged remission, it rarely effects a cure. Consequently, in view of the long-average survival times many patients are now in a position to look forward to many years of life, which may be complicated by symptoms or psychological distress connected with their illness, or its treatment. Studies with general cancer populations point to a greater impact of psychological distress on longer-term (more that 2 years post-diagnosis) survivors, presumably the time period when prognosis becomes more surer. Psychological distress in long-term survivors appears to be correlated with ongoing medical problems resulting from disease or treatment, the degree to which the disease has disrupted life plans and ensuing financial concerns, and social factors such as social isolation, family, or partner problems or bereavements (Serajul Islam, 2018). Using a cross-sectional design, the study by La Nasa et al. (2020) confirmed that haematological cancers have a strong and wide impact on overall HRQoL Perceived physical health is more affected at a younger age by haematological cancers, while perceived mental health is altered irrespective of age. HRQoL of patients with haematological diseases was no worse than that of those with other chronic diseases studied at the time of diagnosis. At the time of diagnosis, patients with chronic diseases usually present worse HRQoL than the healthy population, and all chronically ill patients (haematological and non-haematological alike) have a poor HRQoL, not superior to those of patients with major cardiovascular, neurological, or oncological diseases (Goswami et al., 2020).

16. Healthcare Strategies for Integrated Care

To provide optimal care for patients with hematological malignancies during extraordinary circumstances, integrated management strategies offer a potential solution. Maintaining effective communication with the involved patient and caregivers is crucial. An accurate and rapid COVID-19 diagnostic procedure should be available to patients before chemotherapy or supportive measures. Chemotherapeutic and supportive treatments need to be tailored to the patient's current

health. Whenever possible, short-term oral therapies and pharmacological agents with minimal immunosuppressive effects should be preferred. Whenever feasible, the number of hospital visits required for diagnostic and therapeutic procedures should be minimized to decrease the risk of infection. Remote counselling services (telemedicine) may also be adopted to reduce physical attendance. Patient knowledge of the disease is crucial, and the healthcare system should ensure continuous and transparent communication to strengthen a sense of self-control and responsibility. In summary, early and widespread COVID-19 vaccinations and boosting combined with a multidisciplinary approach and close follow-up remain the key to guarantee the continuity of care for such patients (Tsilingiris et al., 2022). “Integrative hematology” defines a multi-systemic approach to blood diseases. Blood cancers have biological and clinical features distinct from solid tumors. Hematological cancers are characterized by immune deregulation and intrinsic immune alterations, complicating immunological treatment. Some blood cancers follow a better prognosis or a chronic course, such as Hodgkin’s lymphoma and indolent non-Hodgkin’s lymphoma. Diagnostic tools including lymphocyte typing and treatments such as stem cell transplantation are deeply rooted in immune system manipulation, requiring thorough understanding of immune fragility. Scientific tools and conventional therapy are discussed, highlighting integrative approaches currently supported by the literature. Most data remain preliminary, with few clinical trials involving hematological patients. The role of microbiota and nutritional strategies in this vulnerable group is examined (Andreazzoli & Bonucci, 2023).

17. Ethical Considerations in Treatment Approaches

Ethical considerations in treatment approaches for patients with cancer or viral infections who have endocrine disorders or chronic hematological diseases underscore the need to adhere to established guidelines and standards of care (V. Schiappacasse, 2021). Postponing or suspending cancer treatments with evidence of survival and quality-of-life benefits is considered unethical, even during pandemics. Instead, all necessary precautions—such as personalized transport arrangements, rigorous surface disinfection, consistent use of masks, social distancing, and enhanced hand hygiene—should be implemented to minimize contagion risk. Regarding vaccination, the principle of double effect supports the administration of COVID-19 vaccines to cancer patients as a lawful and ethical act, provided that patients’ autonomy is respected and they receive adequate information about the intervention. However, uncertainties remain concerning the efficacy of vaccines in cancer patients, their ability to prevent asymptomatic infection, and reduced effectiveness against certain SARS-CoV-2 variants. Consequently, maintaining stringent hygiene and distancing measures is paramount, particularly for immunosuppressed populations. Adhering to ethical principles in these complex clinical scenarios is essential; nevertheless, other ethical dilemmas arising during the pandemic warrant further in-depth discussion.

18. Public Health Implications of Endocrine and Hematological Disorders

Nonmalignant blood disorders are a diverse group of conditions that affect the cellular and plasma composition of the blood and associated organs such as the spleen and lymph nodes. Haemophilia and sickle cell disease are two of the better-known blood disorders, but there are a large number of others, and many are poorly understood. Public health surveillance of these disorders is necessary to assess the magnitude of the problem, monitor trends over time, and describe patient and provider characteristics and practices . The current surveillance systems are being improved and expanded to provide information on blood disorders, with a broader scope and the use of additional data sources and collection methods. The surveillance for selected blood disorders is also being expanded to include information on emerging complications, their prevalence among various population groups, and previously unmonitored groups such as infants and children. When fully implemented, the enhanced blood disorder surveillance system will provide important information relevant to public health planning and to the care and management of individuals with blood disorders .

The COVID-19 pandemic caused an unprecedented health emergency that overwhelmed care providers and disrupted access to hospitals by patients with chronic illnesses. These circumstances influenced the ability to deliver prompt and effective care to patients with multiple comorbidities including endocrine and hematological disorders, with important implications for disease outcomes. Obesity and hematologic malignancies have been identified as important risk factors for the severity and mortality of COVID-19 infection, and a specific epidemiological link also exists between the former and the latter (Tsilingiris et al., 2022). Furthermore, hematologic neoplasms, especially lymphoid neoplasms, are well-established causes of immune deregulation and enhanced vulnerability to several infections including COVID-19. Management of hematologic cancers is inherently challenging as it requires continuing administration of rigorous treatment schemes and close collaboration among a multidisciplinary team. The COVID-19 outbreak has posed disruptive obstacles in a comprehensive management strategy of these patients, conditioning relevant necessity for alternative approaches. Exploration of potential mechanisms linking obesity with hematologic carcinogenesis, a summary of the obstacles faced, as well as perspectives for improvement of care in similar future crises are presented and actively discussed.

Viral infections impact hematopoiesis through several mechanisms and can have both beneficial and detrimental effects on bone marrow output. Viruses and anti-viral immune responses can affect hematopoiesis either through direct infection of haematopoietic stem and progenitor cells, recognition of virus or viral components by haematopoietic stem and progenitor cells, inflammatory cytokines and chemokines produced during infection or changes in the bone marrow microenvironment. Viruses such as CMV, HCV and human herpes viruses are capable of infecting haematopoietic stem and progenitor cells. CMV exerts myelosuppressive effects and the related human herpes virus HHV7 impairs haematopoietic stem and progenitor cell survival and proliferation. Parvovirus B19 preferentially targets cells of the erythroid lineage and can cause both transient aplastic crisis and a persistent pure red cell aplasia in immunocompromised individuals. Retroviruses such as HIV and HTLV manipulate microRNAs to alter cellular pathways, a process that may result in hematopoietic malignancies. Both HIV and SIV infections induce haematopoietic defects, but the effects of SIV are dependent on the expression of the viral protein Nef. Several of these mechanisms can contribute simultaneously to alterations in haematopoiesis during viral infections (Fernanda Pascutti et al., 2016).

19. Global Perspectives on Endocrine and Hematological Disease Management

Endocrine disorders and hematological diseases represent two broad clinical conditions with considerable immunological implications. Endocrine disorders include a variety of clinical conditions that may affect individuals of all ages worldwide, and are characterized mainly by imbalances in hormone production. Certain endocrine disorders include diabetes, obesity, metabolic syndrome, hypopituitarism, thyroid diseases (hypothyroidism, hyperthyroidism, thyroiditis, and cancer), hyperparathyroidism, adrenal failure, hypercortisolism, and gonadal disorders (hypogonadism, polycystic ovary syndrome, and gynecomastia) (Tsilingiris et al., 2022). Chronic hematological diseases comprise conditions where the homeostasis of blood components and bone marrow function is impaired, including chronic anemia, thrombocytopenia, leukopenia, multiple myeloma, and chronic lymphocytic leukemia. Immune mechanisms provide a link between these two categories of disorders, as they influence the pathophysiology of various types of cancer and viral infections.

Endocrine disorders represent a diverse group of conditions characterized by disruptions in hormone production or secretion, which can substantially influence hematological and immune functions. Of particular interest are diabetes, obesity, metabolic syndrome, and polycystic ovary syndrome, each associated with significant alterations in immune regulation and hematopoiesis. Hypopituitarism affects the pituitary's hormonal output, thereby modulating immune responses.

Thyroid diseases, encompassing hypothyroidism, hyperthyroidism, thyroiditis, and thyroid cancer, impact hematological parameters through complex immune-mediated pathways. Disorders of the parathyroid and adrenal glands, such as hyperparathyroidism, adrenal failure, and hypercortisolism, further perturb immune homeostasis with hematological consequences. Gonadal disorders, including hypogonadism and gynecomastia, influence immunomodulation via sex hormones, thereby affecting blood cell production and function.

20. Collaborative Approaches in Clinical Practice

A multidisciplinary action is essential to deliver, as soon as possible, the best therapeutic strategy and avoid delays that can affect patient prognosis (M. et al., 2019). The spectrum of clinical integration ranges from the unstructured diversification of independently operating institutions to the highly integrated multidisciplinary team with comprehensive integrated pathways for diagnosis, treatment, education and follow-up. Such an approach guarantees sustained, structured and systematic integration of indeed different clinical activities and is able to drastically reduce the fragmentation of care, offer more appropriate and efficacious interventions and deliver better outcomes at acceptable costs (Andreazzoli & Bonucci, 2023).

21. Limitations of Current Research

Despite the growing body of knowledge in this interdisciplinary field, important research limitations persist. Current investigations are often hampered by incomplete characterization of mechanisms through which combined endocrine and hematological abnormalities disrupt immune homeostasis. Variability in the immunopathologies triggered by diverse endocrinopathies and chronic hematological conditions also poses significant challenges for generalization of findings (Fernanda Pascutti et al., 2016). Furthermore, data tend to be fragmented, lacking longitudinal and population-based validation, thereby limiting the robustness of overarching hypotheses. Many studies focus primarily on either haematological or endocrine side effects rather than exploring integrated perspectives, and additional research is required to elucidate the consequences of concomitant pathological states on complex immune networks. Moreover, the clinical implications of endocrine and immune perturbations remain poorly quantified in patients burdened with chronic haematological diseases or malignancies and secondary endocrinopathies. Overall, these insufficiencies constitute a major obstacle to the attainment of safe, integrated interventions and hinder adoption of holistic therapeutic schedules advocated by international authorities.

22. Funding and Resource Allocation for Research

Research funding and allocation of available resources are a huge concern, particularly as the science of endocrine-hematological interactions becomes clear. An analysis of 355,463 PubMed papers (273,526 breast cancer, 81,937 ovarian cancer) identified 91 funding agencies active in breast, and 65 in ovarian cancer research (de-Miguel-Molina et al., 2017). Co-funding patterns, analysed via Social Network Analysis, underscored the National Cancer Institute's role in both fields. The NCI advances policy objectives through collaboration with national and international agencies. Between two sequential funding periods, co-funded Medical Subject Headings (MeSH) remained constant, yet the number of contributing agencies expanded.

Viral hepatitis research funding in the United Kingdom, 1997–2010, amounted to £19.0 million invested in 323 studies, within a database of 6,165 eligible projects from an initial pool of 9,745 (G Head et al., 2014). Total viral hepatitis funding remained stable, but allocations for hepatitis B and C declined, diminishing the investment relative to disease burden. Preclinical investigations constituted the largest share of funded work, although prior analyses have noted a lack of finer-grained categorization. The UK's investment level appears reasonably proportional to viral hepatitis burden, but other research domains remain underfunded.



Figure 3: A conceptual diagram illustrating the trend of viral hepatitis research funding relative to its disease burden in the United Kingdom (1997–2010)

23. Regulatory Frameworks and Guidelines

Twelve years ago, the European Society for Medical Oncology (ESMO) published a position paper articulating its endorsement of international standards of care for the treatment of cancer in patients with HIV, Hepatitis B virus (HBV), and Hepatitis C virus (HCV) infection. These recommendations prioritize avoiding undertreatment, optimizing the patient's overall clinical status during cancer therapy while minimizing interactions between systemic anticancer treatments and concomitant medication, and assessing the potential of cancer therapy to impact organ function and subsequent treatment options across cancer management (P. Hwang et al., 2022). Although treatment guidelines have continued to evolve, alignment on several other key principles has emerged. The gravity of the challenge is underscored by robust evidence that patients with a derived neutrophil-to-leukocyte ratio (dNLR) exceeding 3 combined with lactate dehydrogenase (LDH) levels above 600 U/L—signifying a state of hyperprogression—may benefit from front-line chemotherapy rather than standard-of-care immune checkpoint blockade (A. Wood et al., 2020). Collectively, existing guidance converges on the imperative to comprehensively evaluate cancer patients with viral infections across a broad spectrum of considerations, including clinical, psycho-social, medical, and logistic domains. Furthermore, the value of a multidisciplinary team approach is widely recognized as pivotal in facilitating integrated and seamless patient care.

In response to the absence of a formal regulatory framework, academic oncology in Europe has initiated the establishment of a master framework titled "Cancer and Viral Infections" to delineate a standardized research and policy platform. This initiative is designed to ensure that clinical trials and observational studies maintain full alignment with evolving treatment guidelines, thereby creating robust compliance pathways that harmonize the development of anticancer agents for patients concurrent with viral infections. A parallel effort is underway to adjacently integrate the master framework on Cancer and Viral Infections with a sister framework focused on Cancer and Hematologic Malignancies. Given the fundamental relationship between haemopoiesis and the immune system, it is inevitable that these two independent frameworks will converge. In Europe, the urgency to establish such a comprehensive framework is particularly acute since the European Medicines Agency has left the guidance governing the development of medicine in the field of

cancer completely to the discretion of other Medical Agencies, like the Food and Drug Administration.

24. Interdisciplinary Collaboration in Patient Care

Cancer is often associated with endocrine and hematological disorders that affect disease prognosis (Andreazzoli & Bonucci, 2023). Conversely, viral infections can lead to immunodeficiency, increasing tumor incidence and disturbing endocrine function and blood cell counts. This section examines the case of a middle-aged man diagnosed with lung squamous cell carcinoma during the COVID-19 pandemic. Concurrent endocrine abnormalities, particularly hyperglycemia linked to poor carbohydrate metabolism, were observed. Persistent detection of SARS-CoV-2 RNA in bronchoalveolar lavage fluid suggests a continuous viral presence. The interplay between acute and chronic systemic disorders underscores the need for integrated interdisciplinary care to improve patient prognosis (M. et al., 2019) (Hiemenz & Munker, 2007).

25. Technological Advances in Diagnosis and Treatment

Recent decades have witnessed remarkable technological innovations to overcome the challenges posed by hematologic malignancies. The earliest paradigm shifts emerged from the recognition of the defining genomic lesion in chronic myeloid leukemia – the translocation chromosomal marker, also known as the Philadelphia chromosome – followed by the establishment of polymerase chain reaction techniques to detect minimal residual disease (MRD) and the development of targeted next-generation sequencing assays for leukemia specimens (Kwon & C. S. Yeung, 2024).

Disruptive new technologies entering the field have therefore been transformative in maintaining pace with the ever-growing clinical demand for increased efficiency and accuracy in testing of legacy samples, simultaneous broad evaluation of multiple genes, and resistance mutation detection, allow rapid assessment of repeat samples at the time of clinical management, and deliver precise characterization of emerging subclones. These innovations include shorter turnaround “rapid” sequencing platforms, novel sequencing approaches such as long-read sequencing, technological enhancements of existing platforms enabling increased target coverage at lower cost, and improvements in bioinformatics pipelines that incorporate deeper error modelling and correction. Taken together, they provide faster, higher-quality molecular data for potential downstream use in the assessment of diagnosis, management, and MRD monitoring of hematopoietic malignancies.

Haemato-oncology has always been the leading consultant service driving implementation of molecular diagnostic testing. Beginning with assessment of disease-defining and resistance genomic drivers in chronic myeloid leukemia and MRD tracking of BCR-ABL1 transcripts, examination of somatic variants in specimens from haematological malignancies has evolved in parallel with next-generation sequencing platforms and the expanding availability of commercial gene-targeted panels. The abundance of curated information relating to diagnostic, prognostic, and theranostic importance of variants in genes frequently mutated in haematological malignancies already facilitates clinical interpretation of findings in many scenarios, with systematic incorporation of publicly available resources on variant classification supporting broad use outside of specialist centres. Future efforts will aim to reduce turnaround times further through a combination of improvements in sequencing chemistry and platform design, development of integrated portable laboratory setups, and provision of preanalytical tools as well as quality control reference materials that optimize the sequencing workflow at every step. Developments in machine learning and artificial intelligence are anticipated to underpin a new generation of bioinformatic software packages and variant interpretation tools, enabling specialist review to focus on nonroutine cases and complex variant combinations in addressing some of the most important clinical questions in modern haemato-oncology.

26. Training and Education for Healthcare Professionals

The COVID-19 pandemic exerted psychosocial and work-related stressors on UK haematology registrars, negatively impacting physical health, mental well-being, and academic progression. Training opportunities diminished, notably in outpatient clinics and laboratories, undermining skills development (OA Altohami et al., 2021). Concurrently, education on traumatic brain injury (TBI)-induced growth hormone deficiency (GHD), a prevalent post-TBI sequela, remained inconsistently addressed in US endocrinology fellowship programs. Although program directors recognized its importance, only 57% incorporated formal coverage, and management aspects such as growth hormone replacement were seldom included. Barriers encompassed the condition's rarity, limited curriculum time, absence of clinical guidelines, and insufficient research data. Expertise provision through conferences and professional associations was endorsed to enhance training (Choong Ji Yuen et al., 2023). In rarer settings, transfusion-dependent β-thalassemia major patients encounter severe endocrine disturbances—central hypothyroidism, thyroid cancer, latent hypocortisolism, growth hormone deficiency—driven by iron overload, anemia, and chronic organ damage (Sanctis Vincenzo et al., 2018). A global survey highlighted the necessity for early detection and specialist management of these multifaceted complications.

27. Conclusion

The potency of endocrine disorders in immunological transitions is well illustrated by the role of estrogen in female predominant autoimmune endocrinopathies, although not all endocrine-immune modifications are as detrimental. Local levels of endogenously-produced glucocorticoid hormones following an innate inflammatory insult at the colonic mucosa can down-regulate the immune system to overcome the chronic inflammatory effects in the bowel that are observed in inflammatory bowel disease (IBD). The interaction between endocrine disorders and chronic hematological diseases in cancer and viral infections reveals a complex interplay with notable immunological impact. This interaction underscores the need for multidisciplinary approaches in diagnosis and treatment, as hormonal imbalances and hematological abnormalities can synergistically influence disease progression and patient outcomes. Further research is essential to elucidate the underlying mechanisms and develop targeted therapeutic strategies that address both endocrine and hematological factors in cancer and viral infections.

References:

1. Fernanda Pascutti, M., N. Erkelens, M., & A. Nolte, M. (2016). Impact of Viral Infections on Hematopoiesis: From Beneficial to Detrimental Effects on Bone Marrow Output. ncbi.nlm.nih.gov
2. Nosé, V. (2019). Diagnostic Pathology: Endocrine E-Book: Diagnostic Pathology: Endocrine E-Book. Elsevier Health Sciences. https://2u.pw/jyXQDg
3. Tsilingiris, D., Nasiri-Ansari, N., Spyrou, N., Magkos, F., & Dalamaga, M. (2022). Management of Hematologic Malignancies in the Era of COVID-19 Pandemic: Pathogenetic Mechanisms, Impact of Obesity, Perspectives, and Challenges. ncbi.nlm.nih.gov
4. Silberstein, L. E., & Anastasi, J. (2017). Hematology: Basic Principles and Practice E-Book: Basic Principles and Practice. Elsevier Health Sciences. https://2u.pw/pUqK8x
5. Kedia, S., Raj Bhatt, V., Kumar Rajan, S., Kumar Tandra, P., A El Behery, R., & Akhtari, M. (2014). Benign and Malignant Hematological Manifestations of Chronic Hepatitis C Virus Infection. ncbi.nlm.nih.gov
6. Hudnall, S. D. (2023). Hematology E-Book: A Pathophysiologic Approach. Elsevier Health Sciences. https://2u.pw/Gv3FEt
7. Ostadrahimi, A., Sadra, V., Bahrami, A., Razzaghi, Z., Najafipour, M., Tutunchi, H., & Najafipour, F. (2022). What hematological and endocrinal indicators are important in COVID-19 infection?. ncbi.nlm.nih.gov

8. Michele Carella, A., Marinelli, T., Di Pumpo, M., Ponziano, E., & Benvenuto, A. (2015). Metabolic Disorders in Elderly Patients with Hematologic Malignancies. A Review. [PDF]
9. Zorina, T. & Styche, A. (2015). Infectious Diseases in Cancer Patients: An Overview. ncbi.nlm.nih.gov
10. Fuqua, T. (2024). Essentials of Human Diseases and Conditions-E-Book: Essentials of Human Diseases and Conditions-E-Book. Elsevier Health Sciences. https://2u.pw/S0eeMJ
11. Pandoua Nekoua, M., Debuysschere, C., Vergez, I., Morvan, C., Jespere Mbani, C., Sane, F., Kazali Alidjinou, E., & Hober, D. (2023). Viruses and Endocrine Diseases. ncbi.nlm.nih.gov
12. Veronica Suarez, G., Belen Vecchione, M., Tomas Angerami, M., Sued, O., Claudia Bruttomesso, A., Adelmo Bottasso, O., & Florencia Quiroga, M. (2015). Immunoendocrine Interactions during HIV-TB Coinfection: Implications for the Design of New Adjuvant Therapies. ncbi.nlm.nih.gov
13. Leslie Smith, D. N. P., & BMTCN Susan Smith, D. N. P. (2024). Hematological and Immune Disorders. Sole's Introduction to Critical Care Nursing-E-Book: Sole's Introduction to Critical Care Nursing-E-Book, 451. https://2u.pw/f84AfR
14. Güemes, M., Martín-Rivada, Álvaro, Bascuas Arribas, M., María Andrés-Esteban, E., Molina Angulo, B., Pozo Román, J., & Argente, J. (2022). Endocrine Sequelae in 157 Pediatric Survivors of Hematopoietic Stem Cell Transplantation (HSCT). ncbi.nlm.nih.gov
15. Waller, D. G. (Ed.). (2016). Oncology and Haematology E-Book: Oncology and Haematology E-Book. Elsevier Health Sciences. https://2u.pw/EfTNxD
16. Carvalho, D., Gonçalves, J., Neves, C., & Sérgio Neves, J. (2022). ODP204 Hemochromatosis and endocrine dysfunctions – a case report. ncbi.nlm.nih.gov
17. Hsi, E. D. (2017). Hematopathology E-Book: A Volume in the Series: Foundations in Diagnostic Pathology. Elsevier Health Sciences. https://2u.pw/9lv9m0
18. Andreazzoli, F. & Bonucci, M. (2023). Integrative Hematology: State of the Art. ncbi.nlm.nih.gov
19. Frazier, M. S., & Fuqua, T. (2020). Essentials of Human Diseases and Conditions-E-Book: Essentials of Human Diseases and Conditions-E-Book. Elsevier Health Sciences. https://2u.pw/XjFUcx
20. Serajul Islam, M. (2018). Treat patient, not just the disease: holistic needs assessment for haematological cancer patients. ncbi.nlm.nih.gov
21. Goswami, P., N. Oliva, E., Ionova, T., Else, R., Kell, J., K. Fielding, A., M. Jennings, D., Karakantza, M., Al-Ismail, S., P. Collins, G., McConnell, S., Langton, C., & Salek, S. (2020). Quality-of-life issues and symptoms reported by patients living with haematological malignancy: a qualitative study. ncbi.nlm.nih.gov
22. V. Schiappacasse, G. (2021). Ethical Considerations in Chemotherapy and Vaccines in Cancer Patients in Times of the COVID-19 Pandemic. ncbi.nlm.nih.gov
23. M., G., G., C., Corsi D., C., M., M., C., S., D., F., Ponziani M., C., R., C., A., R., N., M., C., P., D., M., & S., G. (2019). An integrated care pathway for cancer patients with diabetes: A proposal from the Italian experience. [PDF]
24. de-Miguel-Molina, B., W. Cunningham, S., & Ricardo Palop Marro, F. (2017). Analyzing Funding Patterns and Their Evolution in Two Medical Research Topics. [PDF]
25. G Head, M., R Fitchett, J., S Cooke, G., R Foster, G., & Atun, R. (2014). Systematic analysis of funding awarded for viral hepatitis-related research to institutions in the United Kingdom, 1997–2010. ncbi.nlm.nih.gov
26. Davis, J. (Ed.). (2020). Cancer and Rheumatic Diseases, An Issue of Rheumatic Disease Clinics of North America, E-Book: Cancer and Rheumatic Diseases, An Issue of Rheumatic Disease Clinics of North America, E-Book (Vol. 46, No. 3). Elsevier Health Sciences. https://2u.pw/rTxwPo
27. P. Hwang, J., B. Arnold, K., M. Unger, J., Chugh, R., A. Tincopa, M., Loomba, R., Hershman, D., & D. Ramsey, S. (2022). Antiviral therapy use and related outcomes in patients with cancer

and viral infections: results from SWOG S1204. ncbi.nlm.nih.gov Wood, W., S. Neuberg, D., Colton Thompson, J., S. Tallman, M., A. Sekeres, M., H. Sehn, L., Anderson, K., D Goldberg, A., A Pennell, N., M. Niemeyer, C., Tucker, E., Hewitt, K., M Plovnick, R., & K. Hicks, L. (2020). Outcomes of Patients with Hematologic Malignancies and COVID-19 Infection: A Report from the ASH Research Collaborative Data Hub. ncbi.nlm.nih.gov

28. Hiemenz, J. & Munker, R. (2007). Supportive Care in Hematology. ncbi.nlm.nih.gov
29. Kwon, R. & C. S. Yeung, C. (2024). Advances in next-generation sequencing and emerging technologies for hematologic malignancies. ncbi.nlm.nih.gov
30. OA Altohami, M., Langridge, A., MK Shareef, E., & LR Nicolson, P. (2021). The negative impact of the COVID-19 pandemic on UK haematology registrars' well-being and training: Results of a UK nationwide survey. ncbi.nlm.nih.gov
31. Choong Ji Yuen, K., Adiga, R., Kelepouris, N., & Cardenas, J. (2023). THU008 Coverage Of Education And Training Of Traumatic Brain Injury-induced Growth Hormone Deficiency In US Endocrinology Fellowship Programs. ncbi.nlm.nih.gov
32. Sanctis Vincenzo, D., Soliman Ashraf, T., Duran, C., Ploutarchos, T., Shahina, D., Maio Salvatore, D., Heba, E., Yassin Mohamed, A., Aldo, F., Nada, S., Mehran, K., Forough, S., Praveen, S., Shruti, K., Soteroula, C., Alice, A., Constantinos, C., Yurdanur, K., Jaouni Soad, A., Doaa, K., Alyaarubi Saif, A., Lum Su, H., Saveria, C., Salvatore, A., Galati Maria, C., Giuseppe, R., Yasser, W., Elhakim Ihab, Z., Demetris, M., Vassilis, L., & Christos, K. (2018). An ICET-A survey on occult and emerging endocrine complications in patients with β-thalassemia major: Conclusions and recommendations. ncbi.nlm.nih.gov